Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 6, 2019

View Archived Issues

Aging causes cancer, cancer causes aging

PU.1 controls yin and yang of fibrosis

Preclinical results of EphA3 pay-loaded antibody targeting strategy in glioblastoma

CARB-X award supports Polyphor's development of OMPTA candidate

MIR135B is upregulated and promotes inflammation-induced carcinogenesis in epithelial gastric cells

Exicure announces four clinical sites for phase Ib/II study of AST-008

Sotio receives positive VHP decision for first-in-human study of SOC-101

DSMB gives positive safety review for phase II HERACLES study of MaaT-013

First patient treated in phase II study of RP-101

First subject dosed in Moderna's phase I study of mRNA-1944

Protecting the heart, with an iron fist

GF-1061 shows promising activity against Leishmania infantum and Leishmania amazonensis species

VIB-9600 demonstrates promising activity and safety in preclinical models of autoimmune disease

Valerion Therapeutics presents clinical data on VAL-1221 for Pompe disease

EHMT1/2 targeting restores NMDAR function and social behavior in mouse model of autism

Sichuan Kelun-Biotech Biopharmaceutical divulges IDO1 inhibitors

Galapagos and Calchan patent MAP3K5 inhibitors

FDA agrees Cytogel may proceed with phase Ia/IIa study of CYT-1010

Aivita reports new findings on mechanism of action for Root of Cancer technology

Genentech and NewLink Genetics identify TDO inhibitors

Boehringer and Hydra Biosciences patent TRPC5 antagonists

Actinium studies Actimab-A with venetoclax for AML in new phase I/II trial

Bristol-Myers Squibb describes new ROCK2 inhibitors

Entasis holds end-of-phase II meeting with FDA for ETX-2514SUL

Researchers mimic human Batten disease in a porcine model

Capricor resumes CAP-1002 dosing of enrolled HOPE-2 DMD patients

Kamada reports interim data from phase II study of IV-AAT to prevent lung transplant rejection

Phase III trial of margetuximab in HER2-positive metastatic breast cancer meets primary endpoint

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...